LNAI$0.1648-30.20%
Lunai Bioworks Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$829.7K
Float & O/S:
Inst Own:
DilutionScan read 29 of Lunai Bioworks Inc.'s SEC filings and found 3 warrant series, 6 convertibles, 1 ATM program, 1 equity line, 1 shelf registration and 6 completed offerings on file for LNAI. The latest dilution event on file is an agreed share issuance on Sep 2, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
LNAI
Going-concern warning, near-suspended stock
- Business
- WeakGoing concern doubt, $51,992 revenue, $3.6M loss
- Stock risk
- High$2.8M micro-cap, reverse split, shares +63% YoY
Snapshot
Lunai is a pre-clinical, pre-revenue AI biotech that just told the SEC it has substantial doubt about continuing as a going concern.
What's Happening Right Now
- : Lunai's fiscal 2026 10-K disclosed substantial doubt about its ability to continue as a going concern, with less than one month of available cash as of October 13, 2026, a $514 million accumulated deficit, and only $51,992 of revenue from a single customer; the company remains pre-clinical with no approved products.
- : On October 9, 2026, Lunai formally asked Nasdaq to suspend trading in its stock, citing court-discovered evidence of short-selling, locate deficiencies, and failures to deliver from its litigation against Seven Points Capital; no Nasdaq decision had been made as of the filing.
- : On September 22, 2026, Lunai signed an exclusive worldwide license agreement with Tanaist adding human cellular phenotyping to its AI-driven Parkinson's disease discovery platform, with no financial terms disclosed.
- : Lunai amended its Delaware lawsuit to name 10 defendants, including three broker-dealers, alleging a naked short-selling scheme with 29.6 million failed-to-deliver shares and a single session with volume 15.3 times its issued shares; it is seeking treble damages under RICO.
- : On August 4, 2026, Lunai signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics combining AI patient stratification with brain organoid models for Parkinson's disease, targeting an initial data readout in the first half of 2027.
